Drug intelligence / Profile preview

B6I-28Z

Development stage: Unknown
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

B6I-28Z is an investigational chimeric antigen receptor T cell (CAR-T) therapy designed to target CD19, a surface antigen expressed on B cells. The therapy involves engineering a patient's own T cells to express a CAR that recognizes and binds to CD19, leading to targeted destruction of malignant or abnormal B cells. This approach is primarily being explored for the treatment of hematological malignancies such as B-cell lymphomas and acute lymphoblastic leukemia (ALL). The mechanism of action centers on the inhibition and elimination of CD19-positive cells through immune-mediated cytotoxicity[1].

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on B6I-28Z.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on B6I-28Z.

Explore the full profile